Vir Biotechnology, Inc. (VIR)

Market Cap	928.23M
Revenue (ttm)	78.62M
Net Income (ttm)	-533.34M
Shares Out	137.72M
EPS (ttm)	-3.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,473,612
Open	6.86
Previous Close	6.93
Day's Range	6.62 - 7.03
52-Week Range	6.62 - 13.09
Beta	0.46
Analysts	Buy
Price Target	36.40 (+440.06%)
Earnings Date	Oct 31, 2024

About VIR

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Mel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2019
• Employees: 587
• Stock Exchange: NASDAQ
• Ticker Symbol: VIR
• Website: https://www.vir.bio

Analyst Forecast

According to 5 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is $36.4, which is an increase of 440.06% from the latest price.

Price Target

$36.4

(440.06% upside)

Analyst Consensus: Buy